Floatz logo

36 assets in Skin Carcinoma

Therapeutic assets addressing Skin Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Pembrolizumab
Skin Carcinoma
Essen BiotechP2BB (65)
Multiple Vitamins Injection
Skin Carcinoma
Women's College HospitalP3BB (64)
Trametinib
Skin Carcinoma
Cancer Research UKP2/3B (61)
Dabrafenib
Skin Carcinoma
Cancer Research UKP2/3B (60)
Nivolumab
Skin Carcinoma
H. Lee Moffitt Cancer Center and Research InstituteP2B (60)
Binimetinib
Skin Carcinoma
H. Lee Moffitt Cancer Center and Research InstituteP2B (58)
Capivasertib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Crizotinib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Dasatinib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Defactinib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Fexagratinib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Gsk-2636771
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Skin Carcinoma
Peter MacCallum Cancer Centre, AustraliaP2CCC (53)
Ipatasertib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Oncolytic Virus Rp1
Skin Carcinoma
Replimune, Inc.P2CCC (53)
Osimertinib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Palbociclib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Pertuzumab
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Relatlimab
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Sapanisertib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
sm-020 1% gel
Skin Carcinoma
DermBiont, Inc.P2CCC (53)
Trastuzumab
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Trastuzumab Emtansine
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ulixertinib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Vismodegib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Adavosertib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (52)
Taselisib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Copanlisib
Skin Carcinoma
National Cancer Institute (NCI)P2CCC (49)
Ebnk-001
Skin Carcinoma
Essen BiotechP1/2CC (47)
Interleukin-15
Skin Carcinoma
Essen BiotechP1/2CC (47)
Fludeoxyglucose
Skin Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Encorafenib
Skin Carcinoma
H. Lee Moffitt Cancer Center and Research InstituteEarly P1C (39)
Lavender Oil
Skin Carcinoma
San Gallicano Dermatological Institute IRCCSN/AD (30)